Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4482-4490

  Lai, Albert ^b   Kharbanda, Samir ^a   Pope, Whitney B ^b   Tran, Anh ^b   Solis, Orestes E ^b   Peale, Franklin ^a   Forrest, William F ^a   Pujara, Kanan ^a   Carrillo, Jose A ^b   Pandita, Ajay ^a   Ellingson, Benjamin M ^b   Bowers, Chauncey W ^f   Soriano, Robert H ^a   Schmidt, Nils O ^d   Mohan, Sankar ^a   Yong, William H ^b   Seshagiri, Somasekar ^a   Modrusan, Zora ^a   Jiang, Zhaoshi ^a   Aldape, Kenneth D ^e   Mischel, Paul S ^b   Liau, Linda M ^b   Escovedo, Cameron J ^b   Chen, Weidong ^b   Nghiemphu, Phioanh Leia ^b   James, C David ^c   Prados, Michael D ^c   Westphal, Manfred ^d   Lamszus, Katrin ^d   Cloughesy, Timothy ^b   Phillips, Heidi S ^a,c   more..

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; MUTANT PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; EVOLUTION, MOLECULAR; FEMALE; GENES, P53; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION;

EID: 83355163405     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8715     Document Type: Article

References (54)

1. Clarke J, Butowski N, Chang S: Recent advances in therapy for glioblastoma. Arch Neurol 67:279-283, 2010
2. Hambardzumyan D, Squatrito M, Carbajal E, et al: Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev 4:203-210, 2008
3. Alcantara Llaguno S, Chen J, Kwon CH, et al: Malignant astrocytomas originate from neural stem/ progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45-56, 2009
4. Alcantara Llaguno SR, Chen J, Parada LF: Signaling in malignant astrocytomas: Role of neural stem cells and its therapeutic implications. Clin Cancer Res 15:7124-7129, 2009
5. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: A population-based study. Cancer Res 64:6892-6899, 2004 (Pubitemid 39330996)
6. Ohgaki H, Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235-2241, 2009
7. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453, 2007 (Pubitemid 47339290)
8. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
9. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
10. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987- 996, 2005
11. Watanabe T, Nobusawa S, Kleihues P, et al: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153, 2009
12. Nobusawa S, Watanabe T, Kleihues P, et al: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007, 2009
13. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765- 773, 2009
14. Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
15. Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347, 2009
16. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
17. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006 (Pubitemid 43357943)
18. Chen R, Nishimura MC, Bumbaca SM, et al: A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362-375, 2010
19. Schiffman JD, Hodgson JG, VandenBerg SR, et al: Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70:512-519, 2010
20. Günther HS, Schmidt NO, Phillips HS, et al: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897-2909, 2008 (Pubitemid 351620450)
21. Weller M, Felsberg J, Hartmann C, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750, 2009
22. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
23. Pope WB, Sayre J, Perlina A, et al: MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466- 2474, 2005
24. Johnson RA, Wright KD, Poppleton H, et al: Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632-636, 2010
25. Kawaguchi A, Ikawa T, Kasukawa T, et al: Single-cell gene profiling defines differential progenitor subclasses in mammalian neurogenesis. Development 135:3113-3124, 2008
26. Müller FJ, Laurent LC, Kostka D, et al: Regulatory networks define phenotypic classes of human stem cell lines. Nature 455:401-405, 2008
27. von Deimling A, von Ammon K, Schoenfeld D, et al: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26, 1993
28. Watanabe K, Tachibana O, Sata K, et al: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223, 1996; discussion 23-24
29. Yan H, Bigner DD, Velculescu V, et al: Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69:9157-9159, 2009
30. Cooper DN, Youssoufian H: The CpG dinucleotide and human genetic disease. Hum Genet 78: 151-155, 1988 (Pubitemid 18069872)
31. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
32. Ducray F, Marie Y, Sanson M: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:2248-2249, 2009; author reply 2249
33. Zlatescu MC, TehraniYazdi A, Sasaki H, et al: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713-6715, 2001
34. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, et al: Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360-2362, 2004 (Pubitemid 40024350)
35. Paugh BS, Qu C, Jones C, et al: Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061-3068, 2010
36. Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474, 2009
37. Barnea-Goraly N, Menon V, Eckert M, et al: White matter development during childhood and adolescence: A cross-sectional diffusion tensor imaging study. Cereb Cortex 15:1848-1854, 2005 (Pubitemid 41628326)
38. Harris LW, Lockstone HE, Khaitovich P, et al: Gene expression in the prefrontal cortex during adolescence: Implications for the onset of schizophrenia. BMC Med Genomics 2:28, 2009
39. Persson AI, Petritsch C, Swartling FJ, et al: Non-stem cell origin for oligodendroglioma. Cancer Cell 18:669-682, 2010
40. Lindberg N, Kastemar M, Olofsson T, et al: Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 28:2266- 2275, 2009
41. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, et al: PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51:187-199, 2006 (Pubitemid 44063617)
42. Levison SW, Young GM, Goldman JE: Cycling cells in the adult rat neocortex preferentially generate oligodendroglia. J Neurosci Res 57:435-446, 1999 (Pubitemid 29372918)
43. Aguirre A, Dupree JL, Mangin JM, et al: A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 10:990-1002, 2007 (Pubitemid 47185206)
44. Menn B, Garcia-Verdugo JM, Yaschine C, et al: Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26:7907-7918, 2006 (Pubitemid 44315160)
45. Xu W, Yang H, Liu Y, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30, 2011
46. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010
47. Rodin SN, Rodin AS: Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci U S A 95:11927-11932, 1998
48. Green A, Beer P: Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369- 370, 2010
49. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
50. Ward PS, Patel J, Wise DR, et al: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-234, 2010
51. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007 (Pubitemid 46744292)
52. Fujisawa H, Kurrer M, Reis RM, et al: Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 155: 387-394, 1999 (Pubitemid 29370389)
53. Taylor MD, Poppleton H, Fuller C, et al: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323-335, 2005 (Pubitemid 41443417)
54. Gibson P, Tong Y, Robinson G, et al: Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095-1099, 2010